|
|
[Topotecan for pediatric patients with
resistant and recurrent solid tumors]
[Article in Spanish]
Perez Martinez A, Contra T, Scaglione C, Diaz Perez MA, Madero Lopez L
Servicio de Oncologia Infantil. Hospital del Nino Jesus. Madrid.
Espana. antonioperezmartinez@yahoo.es
Background. Topotecan is a cytotoxic drug isolated from the Camptotheca
acuminata tree (from China).
It is able to block the enzyme DNA topoisomerase I and has recently been used in
the treatment of pediatric cancer.
Objectives. To evaluate our preliminary experience with
topotecan in the second line treatment of refractory solid tumors in the
pediatric age group.
Patients and Methods. We performed a retrospective study of 10
patients with various recurrent solid tumors resistant to first line treatment
who were treated with topotecan alone or in association with other
chemotherapeutic agents.
Results. Ten patients with recurrent solid tumors or tumors that were
refractory to conventional treatment (two neuroblastomas, three
rhabdomyosarcoma, two PNET/Ewing's sarcoma, one anaplastic astrocytoma, one soft
tissue sarcoma and one synovial sarcoma) were included.
Five patients showed favorable responses (two had complete responses, two had
partial responses and one had stable disease).
Five patients showed no response.
All patients showed grade II-IV hematological toxicity.
Conclusions.In our experience, topotecan is beneficial in some
refractory or recurrent solid tumors, especially neuroblastomas and soft tissue
sarcomas.
Myelosuppression was tolerable with the use of granulocyte colony-stimulating
factors.
Patients with a complete response to topotecan could benefit from high-dose
chemotherapy and autologous stem cell rescue therapy.
PMID: 12882743 [PubMed]
|
